WEBULL
WebtradeDownload

Rhythm Pharmaceuticals Stock Has The Bull Case Changed After Revenue Growth And Royalty Reset

Simply Wall St · 1d ago
  • Rhythm Pharmaceuticals reported Q3 2026 revenue of US$92.13 million and a narrower net loss of US$41.37 million, supported by IMCIVREE uptake and early Japan commercialization.
  • The amended LG Chem agreement cuts future MC4R portfolio royalties to 1% from 2029 in exchange for US$350 million in staged payments, supported by a new US$750 million term loan facility.
  • We will examine how Rhythm Pharmaceuticals' investment narrative is influenced by Q3 revenue results and the reworked LG Chem royalty agreement.

Look beyond Rhythm Pharmaceuticals and compare this earnings and royalty reset story with other rare-disease and specialty biotech players in our curated 19 high quality undiscovered gems.

Rhythm Pharmaceuticals Investment Narrative Recap

To own Rhythm Pharmaceuticals, investors need to be comfortable with a rare disease obesity franchise built around the MC4R pathway, with IMCIVREE as the commercial anchor and bivamelagon and RM 718 as follow-on assets. The Q3 2026 update, with US$92.13 million in quarterly revenue and a narrower US$41.37 million loss, points to a business still investing heavily to scale.

In the near term, the key swing factor is execution in acquired hypothalamic obesity and early international rollouts such as Japan, while keeping R&D and SG&A from running too far ahead of demand. The main risk remains concentration in IMCIVREE and continued operating losses that may keep pressure on cash needs, even with stronger top line trends.

The amended LG Chem agreement is the announcement that appears most significant. Rhythm Pharmaceuticals agreed to pay US$350 million in staged amounts through 2029. In return, royalties across the MC4R portfolio drop to 1% from 2029, which reshapes the long-term economics if the portfolio reaches meaningful scale.

Backing that deal with a US$750 million term loan facility from KKR's HealthCare Royalty and Blackstone changes the funding mix. This structure provides clearer potential operating leverage on future MC4R sales, but also introduces higher financial obligations and greater interest sensitivity. For potential catalysts, progress in upcoming Phase III studies for bivamelagon and continued IMCIVREE uptake now sit against a more leveraged balance sheet that could magnify both effective execution and any operational setbacks.

Rhythm Pharmaceuticals' current loss of US$210.2 million is set against analyst expectations for earnings of US$370.0 million by 2029, a swing of about US$580 million. That same year is tied to forecasts for US$1.1b in revenue built on 66.3% yearly top line growth.

Uncover why Rhythm Pharmaceuticals' fair value indicates a 30% potential upside to its current price, which could narrow quickly.

NasdaqGM:RYTM 1-Year Stock Price Chart
NasdaqGM:RYTM 1-Year Stock Price Chart

Exploring Other Perspectives

For Rhythm Pharmaceuticals, the more cautious analysts focus on competition risk. They worry that a rival MC4R drug could limit how far IMCIVREE and bivamelagon can run, which helps explain why their pre news models only pointed to US$868.0 million of 2029 revenue and US$33.0 million of earnings. Those figures sit far below the US$1.1b and US$370.0 million that the broader group was using. This shows how wide the range of opinions already was before this quarter and the LG Chem royalty reset. Use this spread as a reminder that reasonable investors can see the same data and reach very different conclusions, and treat the latest earnings and financing update as a fresh checkpoint to compare those competing narratives.

Explore 2 other Rhythm Pharmaceuticals fair value estimates, including one that suggests it could be worth just $134.00!

Form Your Own Verdict

Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

  • A great starting point for your Rhythm Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
  • See our latest analysis for Rhythm Pharmaceuticals. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Rhythm Pharmaceuticals' overall financial health at a glance.

Looking for more Rhythm Pharmaceuticals investment ideas?

If this Rhythm Pharmaceuticals update has sharpened how you think about risk, reward, and capital structure, you can use that same framework to scan a wider field of opportunities with the Simply Wall St Screener.